Context Therapeutics Inc.
CNTX
$2.36
-$0.12-4.84%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.00% | -2.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.10% | 8.73% | |||
| Operating Income | -30.10% | -8.73% | |||
| Income Before Tax | -34.38% | -9.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.38% | -9.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.38% | -9.81% | |||
| EBIT | -30.10% | -8.73% | |||
| EBITDA | -30.12% | -8.74% | |||
| EPS Basic | -34.38% | -9.82% | |||
| Normalized Basic EPS | -34.43% | -9.66% | |||
| EPS Diluted | -34.38% | -9.82% | |||
| Normalized Diluted EPS | -34.43% | -9.66% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||